Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $432.93 million. The enterprise value is $245.86 million.
| Market Cap | 432.93M |
| Enterprise Value | 245.86M |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 32.95 million shares outstanding. The number of shares has increased by 1,637.02% in one year.
| Shares Outstanding | 32.95M |
| Shares Change (YoY) | +1,637.02% |
| Shares Change (QoQ) | +422.56% |
| Owned by Insiders (%) | 5.63% |
| Owned by Institutions (%) | 86.18% |
| Float | 14.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.16, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.16 |
| Quick Ratio | n/a |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -360.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -58.70% |
| Return on Capital (ROIC) | -37.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 13.78 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.64 |
| Average Volume (30 Days) | 121,774 |
Short Selling Information
The latest short interest is 696,160, so 2.11% of the outstanding shares have been sold short.
| Short Interest | 696,160 |
| Short Previous Month | 836,432 |
| Short % of Shares Out | 2.11% |
| Short % of Float | 4.88% |
| Short Ratio (days to cover) | 0.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -72.51M |
| Pretax Income | -69.42M |
| Net Income | -69.42M |
| EBITDA | n/a |
| EBIT | -69.23M |
| Earnings Per Share (EPS) | -$1.59 |
Balance Sheet
The company has $198.31 million in cash and $11.24 million in debt, giving a net cash position of $187.08 million or $5.68 per share.
| Cash & Cash Equivalents | 198.31M |
| Total Debt | 11.24M |
| Net Cash | 187.08M |
| Net Cash Per Share | $5.68 |
| Equity / Book Value | 182.95M |
| Book Value Per Share | 5.55 |
| Working Capital | 176.46M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,637.02% |
| Shareholder Yield | -1,637.02% |
| Earnings Yield | -16.03% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LXEO is $21.20, which is 61.34% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.20 |
| Price Target Difference | 61.34% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -16.58% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |